FDA has approved Foundayo (orforglipron), developed by Eli Lilly and Company, as the first oral non-peptide GLP-1 receptor agonist for chronic weight management
Discover the 6 foundational pillars to cultivate a more caring, compassionate, connected, unified and purpose-filled life.
No referral is needed
Genetic ablation of the Cystine transporter xCT in PDAC cells inhibits mTORC1, growth, survival, and tumor formation via nutrient and oxidative stresses
"Better on average" doesn't mean "better for you." WHAT THE CLINICAL TRIALS SHOW Semaglutide STEP Trials The STEP (Semaglutide Treatment Effect in People with Obesity) program enrolled over 4,500 participants across multiple trials
Look into peer-reviewed research, regulatory status and where products are sourced